Ionis Pharmaceuticals (IONS) Enterprise Value (2009 - 2026)

Ionis Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$2.1 billion for Q2 2026.

• In Q2 2026, Enterprise Value rose 10.28% year-over-year to -$2.1 billion; the TTM figure through Jun 2026 stood at -$2.1 billion (up 10.28% YoY), while the FY2025 annual figure was -$2.7 billion, down 16.53% from the prior year.
• Enterprise Value for Q2 2026 stood at -$2.1 billion, down from -$1.9 billion in the prior quarter.
• The five-year high for Enterprise Value was -$1.9 billion in Q1 2026, with the low at -$2.7 billion in Q4 2025.
• The 5-year median for Enterprise Value is -$2.2 billion (2023), against an average of -$2.2 billion.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value declined 17.98% in 2023, then advanced 12.86% in 2024.
• Ionis Pharmaceuticals' Enterprise Value stood at -$2.0 billion in 2022, then decreased by 17.33% to -$2.3 billion in 2023, then gained by 1.44% to -$2.3 billion in 2024, then declined by 16.53% to -$2.7 billion in 2025, then gained by 23.26% to -$2.1 billion in 2026.
• Business Quant data shows IONS's Enterprise Value at -$2.1 billion in Q2 2026, -$1.9 billion in Q1 2026, and -$2.7 billion in Q4 2025.